IJE Advance Access published online on February 28, 2005
International Journal of Epidemiology, doi:10.1093/ije/dyi023
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, USA; CONRAD, Eastern Virginia Medical School, 1611 North Kent Street, Suite 806, Arlington, VA 22209, USA
* To whom correspondence should be addressed. Background In the continuing effort to introduce antiretroviral therapy in resource-limited settings, there is a need to understand differences between natural history of HIV in different populations and to identify feasible clinical measures predictive of survival. Methods We examined predictors of survival among 836 heterosexuals who were infected with HIV subtype CRF01_AE in Thailand. Results From 1993 to 1999, 269 (49.4%) men and 65 (25.7%) women died. The median time from the estimated seroconversion to death was 7.8 years (95% confidence interval 7.0-9.1). Men and women with enrolment CD4 counts <200 cells/µl had about 2 and 11 times greater risk of death than those with CD4 counts of 200-500 and >500, respectively. Measurements available in resource-limited settings, including total lymphocyte count (TLC), anaemia, and low body mass index (BMI), also predicted survival. Men with two or more of these predictors had a median survival of 0.8 (0.5-1.8) years, compared with 2.7 (1.9-3.3) years for one predictor and 4.9 (4.1-5.2) years for no predictors. Conclusions The time from HIV infection to death appears shorter among this Thai population than among antiretroviral naïve Western populations. CD4 count and viral load (VL) were strong, independent predictors of survival. When CD4 count and VL are unavailable, individuals at high risk for shortened HIV survival may be identified by a combination of low TLC, anaemia, and low BMI. This combination of accessible clinical measures of the disease stage may be useful for medical management in resource-limited settings.
Accepted December 16, 2004
Original paper
HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival
2 Johns Hopkins University, Bloomberg School of Public Health, 615 N. Wolfe Street Room E713, Baltimore, MD 21205, USA
3 Research Institute of Health Science, PO Box 80, Chiang Mai University, Thailand
4 Henry M. Jackson Foundation Suite 600, Rockville, MD 20852, USA
5 Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, USA
6 University of California at San Francisco, San Francisco, CA 94143, USA
7 Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, USA; HIV Vaccine Trials Network, 901 Boren Avenue, Suite 1320, Seattle, WA 98104, USA
K. E. Nelson, E-mail: kenelson{at}jhsph.edu
Abstract
A Commentary has been commissioned to accompany this article and will appear with this paper in the printed issue.
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in Int. J. Epidemiol.:
- Commentary: Sifting through the maze of viral and host diversity and HIV/AIDS clinical progression
- Veronica Miller
Int. J. Epidemiol. 2005 10.1093/ije/dyi090.[Abstract]
This article has been cited by other articles:
|
|
 |
|
  The eligibility for ART in lower income countries Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies Sex Transm Inf, August 1, 2008; 84(Suppl_1): i31 - i36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Taylor, M. E. Sobieszczyk, F. E. McCutchan, and S. M. Hammer The Challenge of HIV-1 Subtype Diversity N. Engl. J. Med., April 10, 2008; 358(15): 1590 - 1602. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Egger, A. Boulle, M. Schechter, and P. Miotti Antiretroviral therapy in resource-poor settings: scaling up inequalities? Int. J. Epidemiol., June 1, 2005; 34(3): 509 - 512. [Full Text] [PDF]
|
|
|
|
|
|
V. Miller Commentary: Sifting through the maze of viral and host diversity and HIV/AIDS clinical progression Int. J. Epidemiol., June 1, 2005; 34(3): 584 - 585. [Full Text] [PDF]
|
|